Effect of Chemotherapy vs No Chemotherapy Pre-transplant to MDS Undergoing Allo-HSCT
Status:
Unknown status
Trial end date:
2020-06-01
Target enrollment:
Participant gender:
Summary
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) appears to be an efficient
tool to cure refractory anemia with excess blasts-1 (RAEB-1), refractory anemia with excess
blasts-2 (RAEB-2) and acute myeloid leukemia (AML) secondary to myelodysplastic syndrome
(MDS). At present, the necessity of chemotherapy pre-transplantation for RAEB-1, RAEB-2 and
AML secondary to MDS (bone marrow blast cells less than 50%) undergoing allo-HSCT remains in
discussion. In this study, the effects of chemotherapy and no chemotherapy
pre-transplantation in patients with RAEB-1, REAB-2 and AML secondary to MDS (bone marrow
blast cells less than 50%) undergoing allo-HSCT are evaluated.
Details
Lead Sponsor:
Nanfang Hospital of Southern Medical University
Collaborators:
Fujian Medical University Union Hospital Guangzhou First People's Hospital Peking University People's Hospital Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University Sun Yat-sen University Third Affiliated Hospital, Sun Yat-Sen University Zhujiang Hospital